Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer progression

• DOI: 10.1007/s13277-015-3045-7
• Publication Date: 2015-01-12T06:18:00Z
• Authors: Xiangrong Deng; Ping Zhou; Xinghua Wei; Matthew Uhlman; Yurong Lin; Xuanting Lin; Sifeng Wu; Pengfei Diao; Haiqing Xie; Jinbao Liu; Keji Xie; Ping Tang
• Keywords: Male; Proteasome Endopeptidase Complex; Prostatic Neoplasms; HSP72 Heat-Shock Proteins; Blood Proteins; Ubiquitinated Proteins; Xenograft Model Antitumor Assays; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; 0302 clinical medicine; Risk Factors; Cell Line, Tumor; Biomarkers, Tumor; Disease Progression; Humans; Aged; bcl-2-Associated X Protein

Previously, we demonstrated that inhibition of proteasomal chymotrypsin-like (CT-like) activity in human prostate cancer (PCa) PC-3 cultures and xenografts results accumulation ubiquitinated proteins, followed by induction cell death. Studies have shown plasma CT-like may be a powerful biomarker for risk stratification hematologic malignancies. We hypothesized circulating proteasomes could also used to stratify patients with PCa. A total 109 suspected PCa underwent prostatic biopsies were enrolled. Subjects divided into non-cancer, low-risk PCa, high-risk groups. Three different markers (CT-like, caspase-like, trypsin-like) measured compared among the three The target Ub-prs, Hsp70, Bax, P27 tissues evaluated. Multivariate analysis was assess whether predictor progression. Only group statistically higher than non-cancer (P < 0.05). expression protein decreased both tissue patients. found an independent ≥55 had 2.15-fold having as those <55 = 0.021). such, it good candidate detection stratification.